Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. 2014;17:227–31.CrossRef
2.
Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17:530–8.CrossRef
3.
Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. 2012;15(Suppl 1):S57–60.CrossRef
4.
Dworakowska D., Grossman A. B. Aggressive and malignant pituitary tumours: state-of-the-art, Endocr Relat Cancer 2018.
5.
Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001;71:542–5.CrossRef
6.
Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging. 2016;6:310–27.PubMedPubMedCentral
7.
Basu S, Alavi A. PET-based personalized management in clinical oncology: an unavoidable path for the foreseeable future. PET Clin. 2016;11:203–7.CrossRef
8.
Choudhury P, Gupta M. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 2017;10:166–70.CrossRef
9.
Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, et al. Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging. 2009;36:1758–66.CrossRef
Metadata
Title
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy
Authors
Majid Assadi
Reza Nemati
Hossein Shooli
Seyed Javad Rekabpour
Iraj Nabipour
Esmail Jafari
Ali Gholamrezanezhad
Abdullatif Amini
Hojjat Ahmadzadehfar
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04578-z

Other articles of this Issue 4/2020

European Journal of Nuclear Medicine and Molecular Imaging 4/2020 Go to the issue

Original Article

Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort

Editorial

166Ho microsphere scout dose for more accurate radioembolization treatment planning

Editorial

Ethical principles for the application of artificial intelligence (AI) in nuclear medicine

Original Article

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

Original Article

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

Original Article

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases